BioSpace News Archive

“We are very pleased with our manufacturing partner Ausun for reaching this milestone as this is a significant step forward in moving towards clinical trials,” said Rod Matheson, Chief Executive Officer.

TARGAN Inc., a biotechnology systems company transforming animal protein production by bringing individualized care technologies to the poultry, swine, and aquaculture markets, announces the appointment of Mr. Clinton A. Lewis, Jr. to its board of directors.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA® (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

HealthTrackRx, the leading polymerase chain reaction (PCR) testing lab, provides clinicians with a menu of respiratory testing solutions focused on diagnostic speed and accuracy.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique discovery platform.

Arcturus Therapeutics Holdings Inc. today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced positive topline results from its Phase 1 clinical trial of A3907, the first oral systemic apical sodium-dependent bile acid transporter (ASBT) inhibitor.

Mustang Bio, Inc. today announced that the company has been added to the NASDAQ Biotechnology Index® (NASDAQ: NBI).

Fortress Biotech, Inc. and its partner company, Helocyte, Inc., (“Helocyte”) today announced that a Phase 2 double-blind, randomized, placebo-controlled clinical trial has been initiated to evaluate the safety and efficacy of Triplex, a cytomegalovirus (“CMV”) vaccine, in eliciting a CMV-specific immune response and reducing CMV replication in people living with HIV.

Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases, announced that it has submitted to the FDA a request for a Type C meeting to solicit feedback on the proposed development pathway for its lead candidate, NP001, for the treatment of ALS.